BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25070543)

  • 21. Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: a systematic review.
    You B; Gan HK; Pond G; Chen EX
    J Clin Oncol; 2012 Jan; 30(2):210-6. PubMed ID: 22162583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. At the crossroads of molecular biology, pathology and the clinic.
    Ferrari A; Bertulli R
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):725-8. PubMed ID: 22716488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines.
    Nishida T; Blay JY; Hirota S; Kitagawa Y; Kang YK
    Gastric Cancer; 2016 Jan; 19(1):3-14. PubMed ID: 26276366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes in randomised controlled trials in prevention and management of carious lesions: a systematic review.
    Levey C; Innes N; Schwendicke F; Lamont T; Göstemeyer G
    Trials; 2017 Nov; 18(1):515. PubMed ID: 29096680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours.
    Barrios CH; Blackstein ME; Blay JY; Casali PG; Chacon M; Gu J; Kang YK; Nishida T; Purkayastha D; Woodman RC; Reichardt P
    Eur J Cancer; 2015 Nov; 51(16):2423-33. PubMed ID: 26248685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
    Blay JY; Bonvalot S; Casali P; Choi H; Debiec-Richter M; Dei Tos AP; Emile JF; Gronchi A; Hogendoorn PC; Joensuu H; Le Cesne A; McClure J; Maurel J; Nupponen N; Ray-Coquard I; Reichardt P; Sciot R; Stroobants S; van Glabbeke M; van Oosterom A; Demetri GD;
    Ann Oncol; 2005 Apr; 16(4):566-78. PubMed ID: 15781488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choosing the target difference ('effect size') for a randomised controlled trial - DELTA
    Cook JA; Julious SA; Sones W; Rothwell JC; Ramsay CR; Hampson LV; Emsley R; Walters SJ; Hewitt C; Bland M; Fergusson DA; Berlin JA; Altman D; Vale LD
    Trials; 2017 Jun; 18(1):271. PubMed ID: 28606102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting.
    Frezza AM; Stacchiotti S; Gronchi A
    BMC Med; 2017 Aug; 15(1):160. PubMed ID: 28826404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Similarities and differences in diagnosis and treatment of gastrointestinal stromal tumors between China, Japan and Korea: from expert consensus to cooperation prospect].
    Cao H; Wang M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):812-819. PubMed ID: 31550818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials.
    Inker LA; Lambers Heerspink HJ; Mondal H; Schmid CH; Tighiouart H; Noubary F; Coresh J; Greene T; Levey AS
    Am J Kidney Dis; 2014 Dec; 64(6):848-59. PubMed ID: 25441438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality of randomized controlled trials reporting in the treatment of sarcomas.
    Toulmonde M; Bellera C; Mathoulin-Pelissier S; Debled M; Bui B; Italiano A
    J Clin Oncol; 2011 Mar; 29(9):1204-9. PubMed ID: 21321290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Real world study and its application in gastrointestinal stromal tumor].
    Cai ZL; Yin Y; Zhang B
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):826-830. PubMed ID: 31550820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
    Leon MB; Piazza N; Nikolsky E; Blackstone EH; Cutlip DE; Kappetein AP; Krucoff MW; Mack M; Mehran R; Miller C; Morel MA; Petersen J; Popma JJ; Takkenberg JJ; Vahanian A; van Es GA; Vranckx P; Webb JG; Windecker S; Serruys PW
    J Am Coll Cardiol; 2011 Jan; 57(3):253-69. PubMed ID: 21216553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bias due to MEasurement Reactions In Trials to improve health (MERIT): protocol for research to develop MRC guidance.
    Miles LM; Elbourne D; Farmer A; Gulliford M; Locock L; McCambridge J; Sutton S; French DP
    Trials; 2018 Nov; 19(1):653. PubMed ID: 30477551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome Reporting in Cardiac Surgery Trials: Systematic Review and Critical Appraisal.
    Goldfarb M; Drudi L; Almohammadi M; Langlois Y; Noiseux N; Perrault L; Piazza N; Afilalo J
    J Am Heart Assoc; 2015 Aug; 4(8):e002204. PubMed ID: 26282561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SEOM Clinical Guideline for gastrointestinal sarcomas (GIST) (2016).
    Poveda A; Martinez V; Serrano C; Sevilla I; Lecumberri MJ; de Beveridge RD; Estival A; Vicente D; Rubió J; Martin-Broto J
    Clin Transl Oncol; 2016 Dec; 18(12):1221-1228. PubMed ID: 27896638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints.
    Saad ED; Buyse M
    Curr Opin Oncol; 2020 Jul; 32(4):384-390. PubMed ID: 32541329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
    Litton JK; Regan MM; Pusztai L; Rugo HS; Tolaney SM; Garrett-Mayer E; Amiri-Kordestani L; Basho RK; Best AF; Boileau JF; Denkert C; Foster JC; Harbeck N; Jacene HA; King TA; Mason G; O'Sullivan CC; Prowell TM; Richardson AL; Sepulveda KA; Smith ML; Tjoe JA; Turashvili G; Woodward WA; Butler LP; Schwartz EI; Korde LA
    J Clin Oncol; 2023 Sep; 41(27):4433-4442. PubMed ID: 37433103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor.
    Özer-Stillman I; Strand L; Chang J; Mohamed AF; Tranbarger-Freier KE
    Clin Cancer Res; 2015 Jan; 21(2):295-302. PubMed ID: 25477532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.